Loading…
Chinese medical-device exporter making patient monitors, ultrasound, ECG machines and veterinary diagnostic devices.
Chinese medical-device exporter making patient monitors, ultrasound, ECG machines and veterinary diagnostic devices.
Sells mostly through local distributors abroad rather than its own foreign sales teams, and wins part of its business in government hospital tenders in emerging markets, so public health budgets and currency moves affect results.
In one line: A Chinese Mindray-lite, exports patient monitors/ultrasound globally.
Moat: narrow (brand, distribution). Established export distribution network across emerging markets.
Headquarters: Shenzhen, Guangdong, China · Founded: 1995 · Employees: 2,475
Size Edan Instruments (300206.SZ) is a China Health Care company (Medical Specialties) with a market value of $1.05B, the 2207th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥12.04 on 6 Nov 2026.
Performance Over six months the shares fell 19.2%, against -7.3% for the median peer and -16.4% for the China market (cap-weighted) — 7th lowest of 20 in its peer set.
Growth Revenue grew 13.7% over the last twelve months (peer median +6.7%); the operating margin is 17.4% (peer median 7.2%).
Valuation It trades at 18.8× forward earnings against a peer median of 36.0× (5th cheapest of 14).
Price implies For today's price to make sense, revenue must grow about 8% a year for seven years (Req g). Recent delivered growth is -3%, so the hurdle is +11 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 18.9 points above its cost of capital (9.5% WACC).
Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥2.16B | CN¥1.98B | CN¥1.82B | CN¥1.92B | CN¥1.72B |
| Revenue growth | — | +9% | -5% | +11% | — |
| Gross profit | CN¥1.28B | CN¥1.12B | CN¥1.01B | CN¥1.06B | CN¥927M |
| EBITDA | n/a | CN¥353M | CN¥197M | CN¥241M | CN¥249M |
| Net income | CN¥370M | CN¥306M | CN¥162M | CN¥221M | CN¥233M |
| Free cash flow | CN¥349M | CN¥273M | CN¥298M | CN¥103M | CN¥299M |
| Capital expenditure | CN¥60.9M | CN¥84.7M | CN¥77.7M | CN¥51.1M | CN¥42.4M |
| Total debt | CN¥27.2M | CN¥30.5M | CN¥17.8M | CN¥17.7M | CN¥10.4M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Edan Instruments 300206.SZ | $1.05B | -19% | +14% | 17% | 18.8× | 7.7% |
| Shenzhen Mindray Bio-Medical Electronics 300760.SZ | $33.4B | +9% | +5% | 28% | 27.1× | 0.9% |
| GE HealthCare GEHC | $37.2B | +30% | +7% | 14% | 15.4× | 4.3% |
| Koninklijke Philips PHIA.AS | $29.8B | +24% | -1% | 10% | 16.5× | 5.7% |
| Sonoscape Medical 300633.SZ | $1.42B | -8% | +18% | 4% | 36.8× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 300206.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +5.2% | +0.3% | 8th highest of 21 |
| 6-month return | -19.2% | -7.3% | 7th lowest of 20 |
| Distance from 52-week high | -28.3% | -33.6% | 10th highest of 21 |
| Revenue growth (TTM) | +13.7% | +6.7% | 8th highest of 20 |
| Operating margin | 17.4% | 7.2% | 6th highest of 20 |
| Forward P/E | 18.8× | 36.0× | 5th cheapest of 14 |
| Growth the price implies (Req g, 7 yrs) | 7.7% | 7.2% | 5th most demanding of 10 |
| Growth delivered (Del g) | -2.9% | +10.3% | lowest of 10 |
| Hurdle (Req g minus delivered) | +10.6 pp | -2.3 pp | 2nd most demanding of 10 |
| ROIC minus cost of capital | +18.9 pp | -1.9 pp | 4th highest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Edan Instruments 300206.SZ | China | $1.05B | -19% | +14% | 17% | 18.8× | 7.7% | -2.9% |
| Integra LifeSciences IART | United States | $1.04B | -4% | +1% | 12% | 5.8× | 5.2% | +3.6% |
| Ceribell CBLL | United States | $1.03B | +32% | +31% | -70% | n/a | n/a | n/a |
| L&C BIO 290650.KS | South Korea | $1.07B | -17% | +53% | 17% | 213.2× | n/a | n/a |
| INKON Life Technology 300143.SZ | China | $1.08B | -14% | +22% | 12% | 55.2× | 12.4% | +12.9% |
| Tinavi Medical Technologies 688277.SS | China | $1.08B | -30% | -2% | -59% | n/a | n/a | n/a |
| PHC 6523.T | Japan | $1.09B | +36% | +3% | 7% | 7.9× | -2.3% | +3.6% |
| SI-BONE SIBN | United States | $1.09B | +98% | +14% | -8% | n/a | n/a | n/a |
| Freenome FRNM | United States | $1.09B | n/a | n/a | n/a | n/a | n/a | n/a |
| Amoy Diagnostics 300685.SZ | China | $1.10B | -14% | +7% | 34% | 20.9× | 6.5% | +10.3% |
| Castle Biosciences CSTL | United States | $993M | +64% | +3% | -9% | n/a | n/a | n/a |
| IRadimed IRMD | United States | $1.10B | 0% | +11% | 32% | 36.0× | 19.1% | +21.5% |
| Beijing Wandong Medical Technology 600055.SS | China | $1.11B | -27% | -11% | -33% | n/a | n/a | n/a |
| Artivion AORT | United States | $985M | -20% | +16% | 7% | 3,912.9× | n/a | n/a |
| HOB Biotech 688656.SS | China | $972M | -22% | +6% | 7% | 188.9× | 40.1% | +12.4% |
| Beijing Strong Biotechnologies 300406.SZ | China | $1.13B | +1% | -4% | 36% | 18.2× | 1.5% | +9.9% |
| Xiangyu Medical 688626.SS | China | $969M | -31% | 0% | 4% | 62.1× | n/a | n/a |
| Eckert & Ziegler EUZ.DE | Germany | $969M | -7% | +4% | 25% | 17.0× | 7.2% | +12.1% |
| Beijing Hotgen Biotech 688068.SS | China | $966M | -38% | +8% | -94% | n/a | n/a | n/a |
| Mingyue Optical Lens 301101.SZ | China | $1.14B | +6% | +14% | 25% | 33.7× | 10.0% | +8.8% |
| Kuros Biosciences KURN.SW | Switzerland | $953M | +3% | +41% | 6% | 73.8× | n/a | n/a |